Cornerstone Therapeutics appoints new CFO
This article was originally published in Scrip
Cornerstone Therapeutics, a speciality pharmaceutical company focused on the acquisition, development and commercialisation of proprietary products for the respiratory and related markets, has appointed Vincent Morgus executive vice-president, finance, and chief financial officer. Mr Morgus joins from Quintiles, where he has been senior vice-president of corporate development since 2003.
You may also be interested in...
No device-related warning letters were released by the US FDA the week of 24 November.
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.